Amneal Pharmaceuticals, Inc. (AMRX)
18.05
+0.37
(+2.09%)
USD |
NASDAQ |
Sep 02, 16:00
18.05
0.00 (0.00%)
After-Hours: 16:04
Amneal Pharmaceuticals Research and Development Expense (TTM) : 176.98M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 176.98M |
| March 31, 2026 | 185.93M |
| December 31, 2025 | 187.59M |
| September 30, 2025 | 205.62M |
| June 30, 2025 | 203.37M |
| March 31, 2025 | 191.46M |
| December 31, 2024 | 190.71M |
| September 30, 2024 | 182.54M |
| June 30, 2024 | 162.81M |
| March 31, 2024 | 164.56M |
| December 31, 2023 | 163.95M |
| September 30, 2023 | 159.77M |
| June 30, 2023 | 168.63M |
| March 31, 2023 | 181.58M |
| December 31, 2022 | 195.69M |
| September 30, 2022 | 205.66M |
| June 30, 2022 | 204.35M |
| March 31, 2022 | 206.46M |
| December 31, 2021 | 201.85M |
| September 30, 2021 | 203.43M |
| June 30, 2021 | 199.02M |
| March 31, 2021 | 191.73M |
| December 31, 2020 | 179.93M |
| September 30, 2020 | 174.52M |
| June 30, 2020 | 168.13M |
| Date | Value |
|---|---|
| March 31, 2020 | 170.57M |
| December 31, 2019 | 188.05M |
| September 30, 2019 | 196.65M |
| June 30, 2019 | 200.82M |
| March 31, 2019 | 203.14M |
| December 31, 2018 | 193.49M |
| September 30, 2018 | 180.34M |
| June 30, 2018 | 179.36M |
| March 31, 2018 | 176.21M |
| December 31, 2017 | 154.49M |
| September 30, 2017 | 131.53M |
| June 30, 2017 | 110.32M |
| March 31, 2017 | 84.88M |
| December 31, 2016 | 81.41M |
| September 30, 2016 | 87.28M |
| June 30, 2016 | 85.79M |
| March 31, 2016 | 81.04M |
| December 31, 2015 | 76.98M |
| September 30, 2015 | 67.72M |
| June 30, 2015 | 68.07M |
| March 31, 2015 | 72.33M |
| December 31, 2014 | 79.11M |
| September 30, 2014 | 79.61M |
| June 30, 2014 | 76.70M |
| March 31, 2014 | 70.99M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Liquidia Corp. | 54.95M |
| Eli Lilly & Co. | 14.60B |
| Viatris, Inc. | 995.00M |
| Pfizer Inc. | 10.82B |
| Indivior Pharmaceuticals, Inc. | 53.00M |